Sanjivani Paranteral Ltd
Sanjivani Paranteral Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
FY'27 total revenue guidance: INR 80-85 crores from base business; INR 60-65 crores from Pune IV plant. For FY'27, base business EBITDA margins are expected in the range of 15.5% to 16.5%, with anticipated recovery from Q1 onwards after March shipment disruptions.
From Sanjivani Paranteral Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- FY'27 total revenue guidance: INR 80-85 crores from base business; INR 60-65 crores from Pune IV plant.
- Base business expected to grow steadily with export operations normalizing and continued expansion in export markets.
- Injectable segment growth: 10%-12% expected.
- Tablet segment growth: 7%-8% expected, with increasing product dossiers and portfolio expansion over 2-3 years.
- Nutraceutical business to ramp up gradually with improved traction in FY'27.
- Pune IV plant ramp-up: production to increase to 70% utilization by Q4 FY'27, aiming for INR 60 crores annual revenue.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Sanjivani Paranteral Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company has recently commissioned a new IV fluid infusion plant in Pune, which started commercial production in December 2025.
- The Pune plant has an annual installed capacity of 60 million bottles, with ramp-up expected to reach 70% utilization by Q4 FY '27.
- Expected revenue from the Pune IV plant for FY '27 is around INR 60-65 crores with EBITDA margins of 17-18%.
- There is ongoing work on dossier filings and approvals for new products, including those for the Pune plant; pipeline approvals were expected by early 2026 but delayed due to regulatory changes.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Sanjivani Paranteral Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Pune IV facility currently has 5 product approvals and 18 products in the pipeline.
- Approval delays have occurred due to government staff transfers and stricter approval processes.
- A significant portion of approvals (a "quite chunk") is expected to be received in the current month (May 2026).
- Out of the 18 products in the pipeline for the Pune plant, about 6 are expected to contribute to revenue.
- Pune IV plant is targeting around INR 60 crore in annual revenue, reflecting a ramp-up and commercial scale-up of new products.
2 more points management made on order book & pipeline
Sanjivani Paranteral Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹11 Cr, net profit ₹1 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Sanjivani Paranteral Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Morepen Laboratories Ltd (Q4 FY26)
472 crore, up 22% year-on-year (YoY) from Rs. Key concall takeaways from Morepen Laboratories Ltd's Q4 FY26 earnings call — and how it ranks against sector…
- Anuh Pharma Ltd (Q4 FY26)
202.12 Cr., a 2.50% increase quarter-on-quarter (Page 14) . Key concall takeaways from Anuh Pharma Ltd's Q4 FY26 earnings call — and how it ranks against…
- Themis Medicare Ltd (Q4 FY26)
Q4 FY26 Net Revenue: ₹76.53 crore, up 6.7% YoY from ₹71.70 crore in Q4 FY25 (Page 8). Key concall takeaways from Themis Medicare Ltd's Q4 FY26 earnings call…
- Remus Pharmaceuticals Ltd (Q4 FY26)
Quarterly Revenue (H2-FY26):** INR 4,534 Mn, up 30.4% YoY from INR 3,478 Mn in H2-FY25 . Key concall takeaways from Remus Pharmaceuticals Ltd's Q4 FY26…
Frequently Asked Questions
What were Sanjivani Paranteral Ltd Q4 FY26 results?
FY'27 total revenue guidance: INR 80-85 crores from base business; INR 60-65 crores from Pune IV plant. For FY'27, base business EBITDA margins are expected in the range of 15.5% to 16.5%, with anticipated recovery from Q1 onwards after March shipment disruptions.
What is Sanjivani Paranteral Ltd share price analysis?
Sanjivani Paranteral Ltd currently shows a neutral. The stock trades at a P/E of 35.2 with a market cap of ₹235 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sanjivani Paranteral Ltd planning capital expenditure?
The company has recently commissioned a new IV fluid infusion plant in Pune, which started commercial production in December 2025.
Keep Sanjivani Paranteral Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.